Efficacy And Safety Of Apatinib As Second-Line Or Beyond Therapy In Patients With Recurrent And/Or Metastatic Head And Neck Squamous Cell Carcinoma.

e17517 Background: The aim of this study was to evaluate the efficacy and safety of apanitib in the treatment of patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) who failed from one or more lines of therapy. Methods: Patients with recurrent and/or metastatic HNSCC after failure of at least one line of therapy were recruited in this open-label exploratory study. Subjects were initially given apatinib 250mg qd until disease progression or unacceptable toxicity. Dose reduction to 125 mg was allowed. Herein, we reported the preliminary results at the cut-of date of Jan 31, 2019. Results: Between Jul 2017 to Dec 2018, 17 patients were enrolled. The median age was 59 years; 94% were male; 88% had more than 2 lines of chemotherapy. The median PFS and OS were 5.71 and 7.86 months, respectively. Most treatment related adverse events (AEs) were in grade ½. The grade ¾ AEs were hypertension (1/17, 5.88%), fistula (2/17, 11.76%), mouth mucositis (2/17, 11.76%), proteinuria (2/17, 11.76%), and f bleeding (6/17, 35.29%). Conclusions: Apatinib showed promising efficiency with tolerable toxicity for recurrent and/or metastatic HNSCC patients who failed from one or more lines of therapy. Clinical trial information: ChiCTR1800015278.